Inflammatory processes in the liver lead to elevated cholesterol levels in people with diabetes, thus promoting subsequent vascular diseases. This is the result of a study by scientists of Helmholtz Zentrum München, Technische Universität München (TUM) and the Collaborative Research Center SFB 1118 at Heidelberg University Hospital. The paper, which has now been published in the journal Cell Reports, presents a previously unknown mechanism.
A little-studied gene may explain how some liver cancer cells obtain the nutrition they need to proliferate, according to new research from the University of Maryland.
A routinely used hospital tool can predict which liver transplant recipients are more likely to do poorly after surgery, according to a study led by Cedars-Sinai. The findings could help doctors identify which patients should receive physical therapy or other targeted interventions to improve their recovery.
An experimental drug protected mice from one of the many ills of our cheeseburger and milkshake-laden Western diet -- non-alcoholic fatty liver disease. The drug reversed liver inflammation, injury and scarring in animals fed a high fat, sugar and cholesterol diet. The diet was designed to replicate the Western fast food diet and recreate the features of non-alcoholic fatty liver disease found in people. The research team plans further testing to move it into human trials.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for hepatobiliary scintigraphy in abdominal pain. This is the third in a series of new AUC developed by SNMMI in its role as a qualified provider-led entity (PLE) under the Medicare Appropriate Use Criteria Program for Advanced Diagnostic Imaging.
Researchers at TMDU found that the YAP molecule is a key mediator in the identification and clearance of damaged cells from the liver. They showed that, in the absence of injury, YAP activation led to hepatocyte proliferation. However, when injury was induced to mouse liver, it instead induced hepatocytes to migrate to the hepatic sinusoids, undergo cell death, and be degraded by the immune system.
A new study from Harvard T.H. Chan School of Public Health and Howard Hughes Medical Institute sheds light on how a key fat-producing enzyme helps protect cells from a toxic form of fat.
In a landmark study of over 50,000 hospital admissions, investigators demonstrated the feasibility of introducing universal screening for alcohol misuse to identify patients at risk. They showed that patients can be easily categorized based on a simple risk score to identify people with high rates of emergency department attendance, recurrent hospital admissions, and high risk of alcohol-related liver disease. These patients can be selectively targeted with effective treatments for alcohol misuse, potentially reducing the burden of alcohol-related harm including alcoholic liver disease.
An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million with chronic hepatitis C infection. But large numbers of them are not aware of their infection as they have not yet been diagnosed. On of World Hepatitis Day, ECDC Director Andrea Ammon highlights the need for Europe to scale-up coverage of testing, prevention interventions and linkage to suitable treatment services to achieve the target of eliminating viral hepatitis by 2030.
Scientists from Princeton University have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections with the goal of testing new therapies.